Impilo

Trusted

http://www.impilo.se/en/

Last activity: 25.08.2026

Active

Categories: DevelopmentFinTechFutureHardwareHealthTechInvestmentITMedTechServiceTechnology

Impilo is a Nordic investment company focused solely on investments in companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries. Our starting point is that our portfolio companies must contribute to a positive and sustainable development of the communities and markets in which they operate in order to remain successful in the long term. This is a conviction that is embedded in our investment strategy since it necessitates a deeper understanding and reduces risks. This way, Impilo invests in people’s opportunities to enjoy healthier lives in the future.

LinkedIn Email

Followers

976

Mentions

Overview

Location

Sweden, Stockholm

Employees

11-50

Founded date

2017

Mentions in press and media 33

Reviews 0

FAQ about Impilo

When was Impilo founded?

Impilo was founded in 2017.

What has the press written about Impilo?

Parsers VC has collected 33 articles mentioning Impilo, among them “Zepzelca® (lurbinectedin) in combination with atezolizumab approved as first-line maintenance therapy for extensive-stage small cell lung cancer in Qatar” (Aug 3, 2026) and “AMBEA AB ( PUBL ) ANNOUNCES A RECOMMENDED PUBLIC OFFER TO THE SHAREHOLDERS OF HUMANA AB TO TENDER ALL THEIR SHARES IN HUMANA AB, AIMING TO COMBINE THE COMPANIES” (Jun 29, 2026).

Is Impilo still active?

Yes, Impilo is active; its latest activity on Parsers VC dates from Aug 25, 2026.

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Aug 3, 2026	Zepzelca® (lurbinectedin) in combination with atezolizumab approved as first-line maintenance therapy for extensive-stage small cell lung cancer in Qatar	Zepzelca® (lurbinectedin) in combination with atezolizumab approved as first-line maintenance therapy for extensive-stage small cell lung cancer in Qatar Mon, Aug 03, 2026 10:30 CET Report this content Stockholm, Sweden, August 3, 2026 – Im...
Jun 29, 2026	AMBEA AB ( PUBL ) ANNOUNCES A RECOMMENDED PUBLIC OFFER TO THE SHAREHOLDERS OF HUMANA AB TO TENDER ALL THEIR SHARES IN HUMANA AB, AIMING TO COMBINE THE COMPANIES	AMBEA AB ( PUBL ) ANNOUNCES A RECOMMENDED PUBLIC OFFER TO THE SHAREHOLDERS OF HUMANA AB TO TENDER ALL THEIR SHARES IN HUMANA AB, AIMING TO COMBINE THE COMPANIES Mon, Jun 29, 2026 07:00 CET Report this content This press release does not con...
Jun 23, 2026	Immedica announces marketing authorization approval in the UAE for Ztalmy® (ganaxolone) for CDKL5 deficiency disorder	Immedica announces marketing authorization approval in the UAE for Ztalmy® (ganaxolone) for CDKL5 deficiency disorder Tue, Jun 23, 2026 08:00 CET Report this content Stockholm, Sweden, June 23, 2026 – Immedica today announced that the Emira...
May 18, 2026	Immedica announces sale of priority review voucher for USD 200 million	Immedica announces sale of priority review voucher for USD 200 million Mon, May 18, 2026 16:00 CET Report this content STOCKHOLM, Sweden, May 18, 2026 - Immedica Pharma announced today that it has completed the sale of its priority review v...
May 8, 2026	Efmody® (modified-release hydrocortisone) receives MHRA approval for adrenal insufficiency in the UK	Efmody® (modified-release hydrocortisone) receives MHRA approval for adrenal insufficiency in the UK Fri, May 08, 2026 11:00 CET Report this content Stockholm, Sweden – May 8, 2026 - Immedica Pharma AB is pleased to announce that the UK Med...
Oct 31, 2025	Immedica submits New Drug Submission (NDS) for Loargys® (pegzilarginase) to Health Canada	Immedica submits New Drug Submission (NDS) for Loargys® (pegzilarginase) to Health Canada Fri, Oct 31, 2025 12:00 CET Report this content Stockholm, Sweden, October 31, 2025 – Immedica today announced that the submitted New Drug Submission ...
Oct 22, 2025	Impilo acquires Oticon Medical from Demant	Impilo acquires Oticon Medical from Demant Wed, Oct 22, 2025 12:32 CET Report this content Stockholm, 2025-10-22 - Impilo is pleased to announce that it has agreed to acquire Oticon Medical, a global leader in bone-anchored hearing solution...
Oct 1, 2025	Immedica and Innovative Medicines Group enter agreement on Loargys® (pegzilarginase) in Latin America	Immedica and Innovative Medicines Group enter agreement on Loargys® (pegzilarginase) in Latin America Wed, Oct 01, 2025 11:00 CET Report this content Stockholm, Sweden, October 1, 2025 – Immedica has entered into an agreement with Innovativ...
Sep 24, 2025	The Nomination Committee for Humana AB's 2026 AGM has been constituted	The Nomination Committee for Humana AB's 2026 AGM has been constituted Wed, Sep 24, 2025 15:43 CET Report this content The members of the Nomination Committee for Humana AB’s Annual General Meeting in 2026 have now been appointed. According...
Aug 29, 2025	Immedica Publishes Favorable Long-Term Data on Loargys® (pegzilarginase)	Immedica Publishes Favorable Long-Term Data on Loargys® (pegzilarginase) Fri, Aug 29, 2025 10:00 CET Report this content Stockholm, August 29, 2025 – Immedica is pleased to announce the publication of favorable long-term data on Loargys (pe...
Aug 18, 2025	Ravicti® (glycerol phenylbutyrate) approved in Saudi Arabia, Qatar and Kuwait	Ravicti® (glycerol phenylbutyrate) approved in Saudi Arabia, Qatar and Kuwait Mon, Aug 18, 2025 12:00 CET Report this content Stockholm, August 18, 2025 Immedica is pleased to announce that Ravicti® (glycerol phenylbutyrate) has received re...
Jul 1, 2025	Gradientech appoints Veronica Byfield Sköld to Board of Directors	Gradientech appoints Veronica Byfield Sköld to Board of Directors Tue, Jul 01, 2025 08:53 CET Report this content The diagnostics company Gradientech today announces the appointment of Veronica Byfield Sköld to its Board of Directors, effec...
Jun 3, 2025	Impilo closes Fund II at the hard cap of €700 million in seven months	Impilo closes Fund II at the hard cap of €700 million in seven months Tue, Jun 03, 2025 12:30 CET Report this content Impilo is pleased to announce the final closing of Fund II, its first Euro-denominated, closed-end fund, at the hard cap o...
May 18, 2025	The Real Estate Tug-of-War: PHP's Bold Move for Assura	In the world of real estate investment trusts (REITs), competition can be fierce. The latest skirmish involves Primary Health Properties (PHP) and Assura, two players in the healthcare property sector. PHP has made a surprising third bid fo...
May 13, 2025	Immedica Publishes Annual & Sustainability Report for 2024	Immedica Publishes Annual & Sustainability Report for 2024 Tue, May 13, 2025 15:12 CET Report this content Stockholm, Sweden – May 13, 2025 – Immedica today announces the publication of its Annual & Sustainability Report for 2024, h...
Apr 25, 2025	The Power of Workplace Culture: A Deep Dive into Employee Satisfaction	In the corporate world, workplace culture is the invisible thread that binds employees to their organizations. It shapes experiences, drives performance, and ultimately determines success. Recent accolades for companies like Linxon Americas...
Apr 25, 2025	Immedica ranked Top 2 among Sweden’s Best Workplaces™ 2025	Immedica ranked Top 2 among Sweden’s Best Workplaces™ 2025 Fri, Apr 25, 2025 10:00 CET Report this content Stockholm, April 25 , 2025 – Immedica has earned a Top 2 ranking among Sweden’s Best Workplaces™ 2025, awarded by Great Place to Work...
Jan 16, 2025	The Nomination Committee's proposal regarding the Board of Directors of Humana for the 2025 AGM	The Nomination Committee's proposal regarding the Board of Directors of Humana for the 2025 AGM Thu, Jan 16, 2025 12:52 CET Report this content Ahead of the Annual General Meeting 2025, The Nomination Committee proposes that the Board of Di...
Dec 30, 2024	Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals, Inc.	Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals, Inc. Mon, Dec 30, 2024 13:00 CET Report this content Stockholm, Sweden and Radnor, Pa. – December 30, 2024 - Immedica Pharma AB (Immedica), a leading global rare disease...
Nov 5, 2024	BLA for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) accepted for priority review by the U.S. FDA	BLA for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) accepted for priority review by the U.S. FDA Tue, Nov 05, 2024 17:00 CET Report this content Stockholm, November 5, 2024: Immedica announces today that the Biologics ...
Oct 25, 2024	Data from the phase 3 SIERRA trial of Iomab-B presented at the annual European Association of Nuclear Medicine (EANM) Congress 2024	Data from the phase 3 SIERRA trial of Iomab-B presented at the annual European Association of Nuclear Medicine (EANM) Congress 2024 Fri, Oct 25, 2024 11:30 CET Report this content Stockholm, October 25, 2024 – Immedica is pleased to announc...
Sep 20, 2024	Joint acquisition of Immedica Pharma completed	Joint acquisition of Immedica Pharma completed Fri, Sep 20, 2024 08:00 CET Report this content Stockholm, September 20, 2024 – KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have today announced the ...
Apr 23, 2024	Leading global investment firm KKR and Nordic healthcare investment firm Impilo enters strategic partnership together with Immedica management	Leading global investment firm KKR and Nordic healthcare investment firm Impilo enters strategic partnership together with Immedica management Tue, Apr 23, 2024 07:15 CET Report this content Stockholm, April 23, 2024 –Investment funds manag...
Feb 2, 2024	Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform	Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform Fri, Feb 02, 2024 15:00 CET Report this content STOCKHOLM, Sweden, 2 February 2024 – Impilo has closed its investment in Avia Pharma Holding AB (“Avia” or the “Com...
Feb 2, 2024	The Nomination Committee's proposal regarding the Board of Directors of Humana for the 2024 AGM	The Nomination Committee's proposal regarding the Board of Directors of Humana for the 2024 AGM Fri, Feb 02, 2024 15:44 CET Report this content Ahead of the Annual General Meeting 2024, The Nomination Committee proposes that the Board of Di...
Aug 16, 2023	Impilo invests in Pelago Bioscience – a fast-growing drug discovery research partner	Impilo invests in Pelago Bioscience – a fast-growing drug discovery research partner Wed, Aug 16, 2023 12:00 CET Report this content STOCKHOLM, Sweden, 16 August 2023 – Impilo invests in Pelago Bioscience AB (“Pelago” or the “Company”) and ...
Aug 16, 2023	Impilo acquires VaccinDirekt – the leading Nordic retail vaccination provider	Impilo acquires VaccinDirekt – the leading Nordic retail vaccination provider Wed, Aug 16, 2023 12:00 CET Report this content STOCKHOLM, Sweden, 16 August 2023 – Impilo has acquired VaccinDirekt from SEB Private Equity and partners with the...
Jun 29, 2023	Impilo invests in Decon – a leading mobility player	Impilo invests in Decon – a leading mobility player Thu, Jun 29, 2023 13:16 CET Report this content June 29, 2023 – Impilo has acquired a majority position in Decon Wheel AB (“Decon”), a developer and producer of high-quality power assist e...
Feb 6, 2023	The Nomination Committee's proposal regarding the Board of Humana for the 2023 AGM	The Nomination Committee's proposal regarding the Board of Humana for the 2023 AGM Mon, Feb 06, 2023 09:28 CET Report this content Ahead of the Annual General Meeting 2023, The Nomination Committee proposes that the Board of Directors, for ...
Apr 12, 2022	Impilo presents its Sustainability Report for 2021	Impilo presents its Sustainability Report for 2021 Tue, Apr 12, 2022 10:36 CET Report this content During 2021, we have taken important steps to create more value from our sustainability efforts by better articulating the health impact of o...
Feb 3, 2022	Impilo invests in Lowenco – a pioneer in ultra-low temperature storage solutions	Impilo invests in Lowenco – a pioneer in ultra-low temperature storage solutions Thu, Feb 03, 2022 08:49 CET Report this content VAMDRUP, Denmark, February 3rd, 2022 – Impilo, together with SHS, have acquired Lowenco A/S (“Lowenco” or the “...
Jan 27, 2022	The Nomination Committee's proposal regarding the Board of Humana for the 2022 AGM	The Nomination Committee's proposal regarding the Board of Humana for the 2022 AGM Thu, Jan 27, 2022 09:00 CET Ahead of the Annual General Meeting 2022 the Nomination Committee of Humana AB proposes that the Board be composed of six directo...